Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a specialty biopharmaceutical company that focuses on the development and commercialization of medicines based on prostones, will release its first quarter 2008 financial results before the opening of the market on Thursday, May 8, 2008 and host a conference call for investors that day at 10:00 a.m. ET.
Ryuji Ueno, M.D., Ph.D., Ph.D., the founder, chairman and chief executive officer of Sucampo Pharmaceuticals, will lead the call, during which management will discuss the Company’s financial results, business outlook and growth strategy.
The call will be accessible on the Company’s website, www.sucampo.com, or by dialing (877) 407-5790 (domestic) or (201) 689-8328 (international). If you are unable to listen to the live call, the webcast will be archived in the “For Investors” section of the Company’s website.
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.
Sucampo Pharmaceuticals is marketing AMITIZA (lubiprostone) in the U.S. for chronic idiopathic constipation in adults and is developing the drug for additional gastrointestinal disorders with large potential markets. AMITIZA was recently approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation in adult women. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd. headquartered in Oxford, UK with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd. located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Contacts:
Mariam E. Morris, 301-961-3400
Chief
Financial Officer
mmorris@sucampo.com
